|Title||Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.|
|Publication Type||Journal Article|
|Year of Publication||2009|
|Authors||Mark T, Martin P, Leonard JP, Niesvizky R|
|Journal||Expert Opin Investig Drugs|
|Date Published||2009 Jan|
|Keywords||Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antigens, Differentiation, B-Lymphocyte, Clinical Trials as Topic, Drug Evaluation, Preclinical, Histocompatibility Antigens Class II, Humans, Immunotherapy, Lymphoma|
BACKGROUND: Non-Hodgkin's lymphoma and multiple myeloma are often incurable and respond to a limited set of treatment options. The selective expression of CD74, the invariant chain of the MHC class II molecule, in these malignancies provides an attractive target for antibody-based therapy.
OBJECTIVE: This review evaluates the preclinical data for milatuzumab, a humanized antibody targeting CD74, as a treatment for non-Hodgkin's lymphomas and multiple myeloma.
METHODS: A review of the literature was carried out using PubMed. Current Phase I protocols using milatuzumab are summarized.
RESULTS/CONCLUSION: Milatuzumab is cytotoxic to lymphoma and multiple myeloma cell lines and mouse-human xenografts. The efficacy dramatically increases when milatuzumab is attached to a toxin or a radioactive agent. Phase I trials of milatuzumab are now underway in human subjects with lymphoma and multiple myeloma.
|Alternate Journal||Expert Opin Investig Drugs|